All In Biotech

Free tool

FAERS Monitor: Sprix

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022382 or its brand name (Sprix, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.

Reports

4,851

Serious

2,626

54% of reports

Hospitalization

1,312

Death reported

263

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective524
  • drug hypersensitivity301
  • nausea272
  • headache263
  • pain250
  • dyspnoea231
  • fatigue226
  • treatment failure205
  • off label use202
  • vomiting176
  • diarrhoea156
  • product dose omission issue148
  • dizziness135
  • eye irritation128
  • eye pain128

Reports by year received

View as table
YearReports
200443
200570
200669
200764
200883
200998
201099
2011166
2012201
201363
201483
2015109
2016431
2017284
2018262
2019369
2020504
2021239
2022310
2023372
2024345
2025346
2026241

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,308 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
treatment failureSignal20510.89.41,806
eye painSignal1289.98.31,010
eye irritationSignal1289.78.1986
drug hypersensitivitySignal3016.86.11,481
product dose omission issueSignal1482.21.995
headache2631.81.699
dyspnoea2311.81.679
pain2501.81.685
drug ineffective5241.71.6169
vomiting1761.61.442
nausea2721.51.345
fatigue2261.31.112
dizziness1351.21.03
diarrhoea1561.00.90
off label use2021.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.